Advertisement

Thrombozytenaggregationshemmer (Update 2019)

  • Thomas C. WascherEmail author
  • Christoph H. Saely
  • den Ausschuss Leitlinien
leitlinien für die praxis
  • 11 Downloads

Zusammenfassung

Akute atherothrombotische Komplikationen tragen im Rahmen der beschleunigten Atherosklerose zur kardiovaskulären Morbidität und Mortalität diabetischer Patienten bei. Die Hemmung der Thrombozytenaggregation kann das Risiko für das Auftreten akuter atherothrombotischer Komplikationen reduzieren. Der vorliegende Artikel stellt die Behandlungsvorschläge der Österreichischen Diabetes Gesellschaft zum Einsatz von Hemmern der Thrombozytenaggregation dar.

Schlüsselwörter

Thrombozyten Aggregationshemmer Akute Atherothrombose Diabetes mellitus 

Inhibition of platelet aggregation (Update 2019)

Summary

Acute thrombotic complications as a key feature of accelerated atherothrombotic disease typically precipitate cardiovascular events and therefore strongly contribute to cardiovascular morbidity and mortality in diabetic patients. Inhibition of platelet aggregation can reduce the risk for acute atherothrombosis. The present article represents the recommendations of the Austrian Diabetes Association for the use of antiplatelet drugs in diabetic patients according to current scientific evidence.

Keywords

Platelets Antiplatelet drugs Acute therothrombosis Diabetes mellitus 

Notes

Interessenkonflikt

T.C. Wascher und C.H. Saely geben an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    The antithrombotic trialists collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.CrossRefGoogle Scholar
  2. 2.
    Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134–41.CrossRefPubMedGoogle Scholar
  4. 4.
    Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O’Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R, Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    The antithrombotic trialists collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.CrossRefGoogle Scholar
  6. 6.
    The ASCEND study collaborative group. Effects of aspiron for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529–39.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  • Thomas C. Wascher
    • 1
    Email author
  • Christoph H. Saely
    • 2
  • den Ausschuss Leitlinien
  1. 1.1. Medizinische AbteilungHanuschkrankenhausWienÖsterreich
  2. 2.Abteilung für Innere Medizin IAkademisches Lehrkrankenhaus FeldkirchFeldkirchÖsterreich

Personalised recommendations